Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Martin Peter Schwalm has a total of 448 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Small-Molecule Modulators of HIPK4 Activity and Proteostasis

    by Zaile Zhuang, Riley K. Togashi, Patrick C. Kearney, Ian Pass, Steven M. Swick, Fu-Yue Zeng, Andrey A. Bobkov, Lynn M. Fujimoto, Shubhankar Dutta, Athina Zerva, et al.

    Homeodomain-interacting protein kinase 4 (HIPK4) is a dual-specificity kinase that is predominantly expressed in differentiating spermatids, required for sperm development, and a promising target for nonhormonal male contraception. Genetic and functional studies have established an essential role for HIPK4 in spermiogenesis, where it acts at least in part through regulation of the F-actin-scaffolded acroplaxome during spermatid head shaping. The direct molecular targets of HIPK4 and their downstream effectors remain poorly defined, and small-molecule probes would be versatile tools for further investigating HIPK4 functions. Synthetic HIPK4 ligands could also be valuable leads for the development of nonhormonal male contraceptives. Here, we report the discovery of a cyanoquinoline-based series of HIPK4 inhibitors with nanomolar potency. Our lead compounds are selective for HIPK4, both within the HIPK family and across the broader kinome, establishing this scaffold as a useful starting point for probe and lead development. Unexpectedly, we found that a subset of these cyanoquinolines also perturbs HIPK4 proteostasis in a cell-type-specific manner. In spermatids, these compounds induce the formation of detergent-insoluble HIPK4 aggregates and promote interactions between this kinase and the autophagy receptor Tax1-binding protein 1 (TAX1BP1), potentially reinforcing a native mechanism of HIPK4 regulation. Together, our findings establish cyanoquinoline ligands as a new chemotype for probing HIPK4 biology and advancing male contraceptive discovery.

  • Open Access

    Cell type–selective targeting by heterobifunctional protein binders via in-cell enrichment

    by Ahmed Bulldan, Min Zheng, Christian Meyners, Patrick L. Purder, Johannes Krieger, Johannes K. Dreizler, Thomas M. Geiger, Max L. Repity, Marte Høen Lein, Ingrid Quist-Løkken, et al.

    Non-catalytic heterobifunctional protein binders promise to expand the range of therapeutic options by establishing complexes between key target proteins and accessory presenter proteins equipped with additional properties. Here, we systematically investigate the rational design of such molecules, explore the biochemical basis of complex formation and determine how they achieve cellular efficacy using the endogenously expressed immunophilin FKBP12 as presenter protein and the transcriptional regulator BRD4 as target protein. We present classes of bifunctional molecules that enable selective, FKBP12-dependent killing of specific cell types at subnanomolar concentrations and allow to differentiate between closely related bromodomains of the BET family. We propose that the strongly potentiated efficacy of these bifunctional compounds is based on cellular enrichment through binding to the highly abundant presenter protein FKBP12, a mechanism we term “CellTrap”. Our findings substantiate the concept that highly expressed, non-essential proteins can be repurposed as selective recruiters to expand therapeutic windows of existing small-molecule inhibitors, opening new avenues for designing targeted drugs with improved cell-type specificity.


  • Open Access

    Macrocyclization of Broad-Spectrum Kinase Inhibitor Bosutinib Leads to Potent and Selective Quinoline-Based HIPK4 Inhibitor AZ137

    by Athina Zerva, Nicolai D. Raig, Zaile Zhuang, Andreas KrämEr, Johannes Dopfer, Riley K. Togashi, Martin Peter Schwalm, Lewis Elson, Julia M. Frischkorn, Benedict-Tilman Berger, et al.

    Homeodomain-interacting protein kinase 4 (HIPK4) remains an understudied member of the dark kinome. While genetic knockout studies suggest its involvement in spermiogenesis and cutaneous squamous cell carcinoma, whether these cellular functions can be recapitulated by pharmacological inhibition remains to be determined. These investigations are currently hampered by a lack of high-quality chemical tools. To address this, we employed a rational design strategy utilizing macrocyclization of a bosutinib-based scaffold. Systematic optimization led to the discovery of AZ137 (28e), a potent and selective HIPK4 inhibitor (IC50: 11 nM; cellular EC50: 76 nM). AZ137 exhibits exceptional selectivity across three comprehensive orthogonal panels, high solubility, and no detectable cytotoxicity. Its cellular activity was confirmed in cell-based assays of HIPK4-dependent F-actin remodeling. Together with a negative control compound, this probe set provides a foundational framework for validating HIPK4 as a therapeutic target and a high-quality resource to elucidate its roles in normal physiology and disease.


  • Open Access

    Riding toward Selectivity: Optimization of Covalent 7-Azaindole-Based BMX Kinase Inhibitors

    by Xiaojun Julia Liang, Claudia Albertini, Thales Kronenberger, Ekaterina Shevchenko, Alexander Rasch, Benedict-Tilman Berger, Martin Schwalm, Lena Marie Berger, Andreas Krämer, Ricardo A. M. Serafim, et al.

    The tyrosine kinase expressed in hepatocellular carcinoma (TEC) family comprises five nonreceptor tyrosine kinases─BTK, ITK, BMX, TXK, and TEC─with key roles in immune signaling. Although BTK and ITK have been extensively studied, selective inhibitors for TEC, TXK, and BMX remain scarce. Recently, we identified 7-azaindole-based covalent BMX inhibitors with potent inhibitory activity and robust cellular target engagement but limited selectivity across TEC family members, especially BTK. Here, we describe a new generation of BMX inhibitors designed to exploit subtle structural differences between BMX and BTK by incorporating diverse N-acylamino substituents at the azaindole 5-position or variations at the linker and warhead. Our compounds display subnanomolar BMX potency and improved selectivity over BTK and other TEC kinases. Key compound 11i showed strong cellular target engagement, good in vitro metabolic stability, a favorable kinome profile, and rapid covalent inactivation kinetics, positioning it among the best BMX chemical probes currently available.

  • Open Access

    Riding toward Selectivity: Optimization of Covalent 7-Azaindole-Based BMX Kinase Inhibitors

    by Xiaojun Julia Liang, Claudia Albertini, Thales Kronenberger, Ekaterina Shevchenko, Alexander Rasch, Benedict-Tilman Berger, Martin Schwalm, Lena Marie Berger, Andreas Krämer, Ricardo A. M. Serafim, et al.

    The tyrosine kinase expressed in hepatocellular carcinoma (TEC) family comprises five non-receptor tyrosine kinases – BTK, ITK, BMX, TXK, and TEC – with key roles in immune signalling. Although BTK and ITK have been extensively studied, selective inhibitors for TEC, TXK, and BMX remain scarce. Recently, we identified 7-azaindole-based covalent BMX inhibitors with potent inhibitory activity and robust cellular target engagement but limited selectivity across TEC family members, especially BTK. Here, we describe a new generation of BMX inhibitors designed to exploit subtle structural differences between BMX and BTK by incorporating diverse N-acylamino substituents at the azaindole 5-position or variations at the linker and warhead. Our compounds display subnanomolar BMX potency and improved selectivity over BTK and other TEC kinases. Key compound 11i showed strong cellular target engagement, good in vitro metabolic stability, a favourable kinome profile, and rapid covalent inactivation kinetics, positioning it among the best BMX chemical probes currently available.

  • Open Access

    On the Scope of DCAF1-Recruiting PROTACs Degrading Protein Kinases

    by Janik Weckesser, Nebojša Miletić, Saran Aswathaman Sivashanmugam, Uli Ohmayer, Martin Steger, Bachuki Shashikadze, Paul Gehrtz, Andrea Unzue Lopez, Ansgar Wegener, Timo Yoshua Dietz, et al.

    Proteolysis-targeting chimeras (PROTACs) have emerged as a novel drug modality, but their development currently relies on a limited number of E3 ligase ligands, primarily targeting CRBN and VHL. Conversely, current validation studies on novel E3 ligase ligands are typically limited to a few highly degradable targets, like BRD4. Here, we used our previously established workflow for E3 ligase ligand validation, employing promiscuous kinase PROTACs, to evaluate the potential of recruiting DCAF1 for PROTAC development. Our study revealed the DCAF1-dependent degradation of a diverse set of kinases, which were validated in orthogonal assays. In a comparative analysis, we identified a significant overlap between the degradable kinome of DCAF1- versus CRBN-recruiting PROTACs, suggesting alternative design strategies for PROTACs using available structurally diverse DCAF1 ligands. Moreover, ubiquitinomics analysis of the PROTAC-induced ubiquitination patterns provided insight into substrate- and isoform-selective degradation. The presented data will establish DCAF1-recruiting PROTACs as a versatile design strategy for future degrader development.


  • Open Access

    p21-Activated Kinase (PAK) Group I-Targeting Inhibitors Promote the Dimeric Conformation in Live Cells

    by Theresa A. L. Ehret, Benedict-Tilman Berger, Nicolai Raig, Felix Nowotka, Neele Manik, Viktoria Morasch, Andreas Krämer, Lewis Elson, Thiago Loreto Matos, Susanne Müller, et al.

    P21-activated kinases (PAKs) are involved in a broad range of cellular processes and are emerging drug targets. The human PAK family consists of 6 kinases, divided into group I (PAK1-3) and group II (PAK4-6), both families are regulated by distinct activation mechanisms and interaction partners. Currently, there are no assays available enabling the study of on-target activity for all PAK isoforms in cells. To this end, we developed a series of NanoLuc- and HaloTag-based bioluminescence resonance energy transfer assays to quantify inhibitor target engagement and dimerization of PAK isoforms in living cells. Interestingly, we found evidence that inhibitors might promote the formation of group I PAK dimers. Thus, our data uncovered a live-cell mechanism by which inhibitors modulate this dimeric conformation and provide new tools for future PAK inhibitor design.


  • Open Access

    Identification and Validation of 3-Cyano-Quinoline Ligands Targeting Integrin-Linked Kinase (ILK)

    by Francesco Aleksy Greco, Kamal Rayees Abdul Azeez, Marko Mitrović, Saran Aswathaman Sivashanmugam, Martin Peter Schwalm, Franziska Preuss, Deep Chatterjee, Viktoria Morasch, Sebastian Mathea, Thomas Hanke, et al.

    Integrin-linked kinase (ILK) is a pseudokinase that directly interacts with β-integrins and plays a pivotal role in regulating focal adhesion function. ILK has been implicated in the development of various diseases, particularly cancer. However, currently, no validated ligands for ILK have been reported. Here, we describe the identification of 3-cyano-quinolines that potently bind to ILK (KD = ∼250 nM), and crystallographic studies revealed a type I binding mode. A medicinal chemistry campaign exploring structure–activity relationships (SAR) using a robust parallel synthesis approach provided comprehensive SAR and identified regions amenable to modification. In addition, we demonstrated that the optimized 3-cyano-quinoline 1 (DHP) modulates actin cytoskeletal dynamics. This work highlights the first validated ILK ligands and establishes a foundation for future translational efforts, such as the development of selective PROTACs targeting ILK for degradation by the ubiquitin system.

  • Open Access

    Small-molecule modulators of HIPK4 activity and proteostasis

    by Zaile Zhuang, Riley K. Togashi, Patrick Kearney, Ian Pass, Steven M. Swick, Fu-Yue Zeng, Andrey A. Bobkov, Lynn M. Fujimoto, Shubhankar Dutta, Athina Zerva, et al.

    Homeodomain-interacting protein kinase 4 (HIPK4) is a dual-specificity kinase that is predominantly expressed in differentiating spermatids, required for sperm development, and a promising target for nonhormonal male contraception. Genetic and functional studies have established an essential role for HIPK4 in spermiogenesis, where it acts at least in part through regulation of the F-actin-scaffolded acroplaxome during spermatid head shaping. The direct molecular targets of HIPK4 and their downstream effectors remain poorly defined, and small-molecule probes would be versatile tools for further investigating HIPK4 functions. Synthetic HIPK4 ligands could also be valuable leads for the development of nonhormonal male contraceptives. Here, we report the discovery of a cyanoquinoline-based series of HIPK4 inhibitors with nanomolar potency. Our lead compounds are selective for HIPK4, both within the HIPK family and across the broader kinome, establishing this scaffold as a useful starting point for probe and lead development. Unexpectedly, we found that a subset of these cyanoquinolines also perturbs HIPK4 proteostasis in a cell type-specific manner. In spermatids, these compounds induce the formation of detergent-insoluble HIPK4 aggregates and promote interactions between this kinase and the autophagy receptor Tax1-binding protein 1 (TAX1BP1). Together, our findings establish cyanoquinoline ligands as a new chemotype for probing HIPK4 biology and advancing male contraceptive discovery.


  • Open Access

    Targeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitors

    by Nikolas Klink, Sebastian Urban, Johanna A. Seier, Bikash Adhikari, Martin P. Schwalm, Juliane Müller, Madeleine Dorsch, Philine Steinbach, Jennifer Jung, Markus Vogt, et al.

    Proteolysis-targeting chimeras (PROTACs) co-op the ubiquitin system for targeted protein degradation, creating opportunities to interrogate cellular functions of proteins through “chemical knockdown”. However, matched pairs of protein degraders and inhibitors, that possess high specificity and chemical complementarity, for individual components of the ubiquitin system have remained scarce. This includes reagents to modulate activity and abundance of deubiquitinases (DUBs). Here, using an integrated chemical biology approach, we explore cellular functions of the DUB USP7 as a case study by comparing inhibition and degradation in melanoma and pancreatic cancer cells. Through the synthesis of a degrader library, we identify and characterize potent USP7 PROTACs for each cancer type. Proteomic and cellular analyses reveal that selective USP7 degradation modulates both shared and distinct protein sets across both cancers without affecting cell growth. In contrast, prolonged inhibitor treatment induces USP7-independent proteomic and metabolic dysregulation, highlighting important caveats for the cellular use of hydroxypiperidine-based USP7 inhibitors. Collectively, our work provides a comprehensively characterized chemical toolbox to distinguish on-target phenotypes which will aid the understanding of USP7 in malignant diseases. More broadly, our data emphasize the importance of increased specificity via PROTAC-mediated degradation and the potential of this modality to elucidate cell-line specific functions of DUBs.